Dosage & administration
Dose, administration, missed doses, and injection technique.
Dosage
The recommended dosage of Pegpesen® is 0.14 mg/kg once weekly based on body weight. It is preferable to administer the medication on the same day of each week. Individualize dosage for each patient based on growth response each 3–6 months.
Missed doses
If you miss a dose of Pegpesen®, the missed dose should be administered within 3 days as soon as possible after the scheduled dosing day. If more than 3 days have passed from the scheduled day, skip the dose and administer the next dose on the regularly scheduled dosing day. In both cases, the patient can then resume their scheduled once-weekly dosing regimen.
Route & injection sites
For subcutaneous injection only.
Pegpesen® can be administered subcutaneously in the abdominal wall, mid-outer thigh, or upper arm. Avoid repeating injections at the same site within 30 days, and injection sites should be more than 2 cm apart.
Prefilled cartridge + electronic pen (TopPen I)
Before injection: Disinfect the injection site as instructed by your healthcare provider.
During injection: Injection should be carried out using the matching electronic pen injector (Model TopPen I). For installation and use of this product, strictly follow the electronic pen injector instructions.
After injection: Handle the used cartridge with caution to prevent accidental needle-stick injuries.
See Injector (TopPen I) for device capabilities, accuracy specification, and connectivity.
Standard prefilled syringe or vial (without cartridge pen)
Before injection: Disinfect per healthcare instruction.
During injection: Pegpesen® should be injected slowly. After completing the injection, leave the needle under the skin for at least 5 seconds to make sure the full dose is delivered. For product packaged in vial, single-use sterile syringes should be used to prevent contamination.
After injection: Handle used needles with caution to prevent needle-stick injuries.
Pediatric use
Growth failure due to GHD in pediatric patients aged 3 and above should be treated with Pegpesen® following medical advice.
Pregnancy, lactation, geriatrics
No available clinical study data on Pegpesen® use in pregnant and lactating women.
No available clinical study data on Pegpesen® use in geriatric patients.